

NA Hereditary Cancer Testing Market - Industry Trends and Forecast to 2029

Market Report | 2022-10-01 | 149 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

North America hereditary cancer testing market is projected to register a CAGR of 13.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

North America Hereditary Cancer Testing Market, By Test Type (Multi Panel Set, and Single-Site Genetic Test) Diagnosis Type (Biopsy, Imaging, Lab Tests) Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray) Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Vol-Hippel Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes) End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others) Distribution Channel (Direct Tender, Retail Sales) Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029

Some of the factors boosting the growth of the hereditary cancer testing market are:

- Rising incidence of hereditary cancer
- Increased demand for non-invasive testing methods

Market Players:

The key market players for North America hereditary cancer testing market are listed below:

- Invitae Corporation
- Illumina, Inc.
- Natera, Inc.
- CENTOGENE N.V.
- 4baseCare
- Biocartis
- Fulgent Genetics
- Ambry Genetics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- BioReference
- PerkinElmer Inc.
- LifeLabs
- Abbott
- BIO-HELIX
- Cepheid
- Eurofins Scientific

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	14
1.1 OBJECTIVES OF THE STUDY	14
1.2 MARKET DEFINITION	14
1.3 OVERVIEW OF THE NORTH AMERICA HEREDITARY CANCER TESTING MARKET	14
1.4 CURRENCY AND PRICING	16
1.5 LIMITATIONS	16
1.6 MARKETS COVERED	17
2 MARKET SEGMENTATION	20
2.1 MARKETS COVERED	20
2.2 GEOGRAPHICAL SCOPE	21
2.3 YEARS CONSIDERED FOR THE STUDY	22
2.4 DBMR TRIPOD DATA VALIDATION MODEL	23
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	26
2.6 MULTIVARIATE MODELLING	27
2.7 MARKET END USER COVERAGE GRID	28
2.8 SOURCE LIFELINE CURVE	29
2.9 DBMR MARKET POSITION GRID	30
2.10 VENDOR SHARE ANALYSIS	32
2.11 SECONDARY SOURCES	33
2.12 ASSUMPTIONS	33
3 EXECUTIVE SUMMARY	34
4 PREMIUM INSIGHT	37
4.1 PESTEL ANALYSIS	38
4.2 PORTER'S FIVE FORCES	39
5 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: REGULATIONS	40
6 MARKET OVERVIEW	45
6.1 DRIVERS	47
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER	47
6.1.2 INCREASE IN THE GERIATRIC POPULATION	47
6.1.3 RISING HEALTHCARE SPENDING	48
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING	48
6.2 RESTRAINTS	49
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING	49
6.2.2 LACK OF SKILLED PROFESSIONALS	50

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.3 OPPORTUNITIES	50
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS	50
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS	51
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS	52
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES	52
6.4 CHALLENGES	53
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING	53
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS	54
7 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE	55
7.1 OVERVIEW	56
7.2 MULTI PANEL TEST	59
7.3 SINGLE-SITE GENETIC TEST	59
8 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE	60
8.1 OVERVIEW	61
8.2 BIOPSY	64
8.2.1 NEEDLE BIOPSIES	64
8.2.2 ENDOSCOPIC BIOPSIES	64
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY	65
8.2.4 LAPAROTOMY AND THORACOTOMY	65
8.2.5 OTHERS	65
8.3 IMAGING	65
8.3.1 MAGNETIC RESONANCE IMAGING (MRI)	66
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN	66
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN	66
8.3.4 NUCLEAR SCAN	66
8.3.5 ULTRASOUND	66
8.3.6 X-RAYS	66
8.4 LAB TESTS	67
8.4.1 BLOOD	67
8.4.2 URINE	67
8.4.3 OTHERS	67
9 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY	68
9.1 OVERVIEW	69
9.2 POLYMERASE CHAIN REACTION (PCR)	72
9.3 SEQUENCING	72
9.4 MICRO ARRAY	73
10 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE	74
10.1 OVERVIEW	75
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME	78
10.3 COWDEN SYNDROME	78
10.4 LYNCH SYNDROME	79
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME	79
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)	80
10.7 LI-FRAUMENI SYNDROME	80
10.8 VON HIPPEL-LINDAU DISEASE	81
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME	81
11 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USER	82

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1 OVERVIEW	83
11.2 HOSPITALS	86
11.3 CLINICS	86
11.4 DIAGNOSTIC CENTERS	87
11.5 RADIOLOGY CENTERS	87
11.6 LABORATORIES	88
11.7 OTHERS	88
12 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL	89
12.1 OVERVIEW	90
12.2 DIRECT TENDER	93
12.3 RETAIL SALES	93
13 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY REGION	94
13.1 NORTH AMERICA	95
13.1.1 U.S.	102
13.1.2 CANADA	106
13.1.3 MEXICO	110
14 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE	114
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	114
15 SWOT ANALYSIS	115
16 COMPANY PROFILE	116
16.1 ABBOTT	116
16.1.1 COMPANY SNAPSHOT	116
16.1.2 REVENUE ANALYSIS	116
16.1.3 COMPANY SHARE ANALYSIS	117
16.1.4 PRODUCT PORTFOLIO	117
16.1.5 RECENT DEVELOPMENTS	117
16.2 ILLUMINA, INC. (2021)	118
16.2.1 COMPANY SNAPSHOT	118
16.2.2 REVENUE ANALYSIS	118
16.2.3 COMPANY SHARE ANALYSIS	119
16.2.4 PRODUCT PORTFOLIO	119
16.2.5 RECENT DEVELOPMENTS	120
16.3 PERKINELMER INC. (2021)	121
16.3.1 COMPANY SNAPSHOT	121
16.3.2 REVENUE ANALYSIS	121
16.3.3 COMPANY SHARE ANALYSIS	122
16.3.4 PRODUCT PORTFOLIO	122
16.3.5 RECENT DEVELOPMENTS	122
16.4 LIFELABS GENETICS	123
16.4.1 COMPANY SNAPSHOT	123
16.4.2 COMPANY SHARE ANALYSIS	123
16.4.3 PRODUCT PORTFOLIO	124
16.4.4 RECENT DEVELOPMENTS	124
16.5 EUROFINS SCIENTIFIC (2021)	125
16.5.1 COMPANY SNAPSHOT	125
16.5.2 REVENUE ANALYSIS	125
16.5.3 COMPANY SHARE ANALYSIS	126

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.5.4	PRODUCT PORTFOLIO	126
16.5.5	RECENT DEVELOPMENT	126
16.6	AMBRY GENETICS	127
16.6.1	COMPANY SNAPSHOT	127
16.6.2	REVENUE ANALYSIS	127
16.6.3	PRODUCT PORTFOLIO	128
16.6.4	RECENT DEVELOPMENTS	128
16.7	BIOCARTIS	129
16.7.1	COMPANY SNAPSHOT	129
16.7.2	REVENUE ANALYSIS	129
16.7.3	PRODUCT PORTFOLIO	130
16.7.4	RECENT DEVELOPMENTS	130
16.8	BIO-HELIX	131
16.8.1	COMPANY SNAPSHOT	131
16.8.2	PRODUCT PORTFOLIO	131
16.8.3	RECENT DEVELOPMENTS	131
16.9	BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021)	132
16.9.1	COMPANY SNAPSHOT	132
16.9.2	REVENUE ANALYSIS	132
16.9.3	PRODUCT PORTFOLIO	133
16.9.4	RECENT DEVELOPMENT	133
16.10	CENTOGENE N.V. (2021)	134
16.10.1	COMPANY SNAPSHOT	134
16.10.2	REVENUE ANALYSIS	134
16.10.3	PRODUCT PORTFOLIO	135
16.10.4	RECENT DEVELOPMENT	135
16.11	CEPHEID	136
16.11.1	COMPANY SNAPSHOT	136
16.11.2	PRODUCT PORTFOLIO	136
16.11.3	RECENT DEVELOPMENT	136
16.12	FULGENT GENETICS	137
16.12.1	COMPANY SNAPSHOT	137
16.12.2	REVENUE ANALYSIS	137
16.12.3	PRODUCT PORTFOLIO	138
16.12.4	RECENT DEVELOPMENT	138
16.13	INVITAE CORPORATION	139
16.13.1	COMPANY SNAPSHOT	139
16.13.2	REVENUE ANALYSIS	139
16.13.3	PRODUCT PORTFOLIO	140
16.13.4	RECENT DEVELOPMENT	140
16.14	NATERA, INC. (2021)	141
16.14.1	COMPANY SNAPSHOT	141
16.14.2	REVENUE ANALYSIS	141
16.14.3	PRODUCT PORTFOLIO	142
16.14.4	RECENT DEVELOPMENTS	142
16.15	4BASECARE.	144
16.15.1	COMPANY SNAPSHOT	144

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.15.2 PRODUCT PORTFOLIO	144
16.15.3 RECENT DEVELOPMENTS	145
17 QUESTIONNAIRE	146
18 RELATED REPORTS	149

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

NA Hereditary Cancer Testing Market - Industry Trends and Forecast to 2029

Market Report | 2022-10-01 | 149 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-12"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com